L3VLUP
ProSign in

RGEN · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RGENARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RGEN
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterRGENARGX
Q3 202011 holders, $1.1bn8 holders, $3.6bn
Q4 202011 holders, $1.6bn7 holders, $4.1bn
Q1 202113 holders, $1.4bn8 holders, $4.1bn
Q2 202113 holders, $1.5bn9 holders, $4.6bn
Q3 202112 holders, $2.0bn8 holders, $4.5bn
Q4 202114 holders, $1.9bn9 holders, $5.3bn
Q1 202210 holders, $1.5bn8 holders, $5.3bn
Q2 20228 holders, $1.8bn13 holders, $6.5bn
Q3 20229 holders, $1.7bn14 holders, $5.3bn
Q4 20229 holders, $1.7bn13 holders, $5.5bn
Q1 20238 holders, $1.6bn13 holders, $5.9bn
Q2 20236 holders, $1.1bn18 holders, $6.6bn
Q3 20237 holders, $1.6bn21 holders, $8.7bn
Q4 20238 holders, $1.6bn17 holders, $6.3bn
Q1 20248 holders, $1.5bn13 holders, $6.8bn
Q2 202410 holders, $959m14 holders, $7.9bn
Q3 202410 holders, $1.3bn13 holders, $10.7bn
Q4 202411 holders, $1.7bn14 holders, $12.3bn
Q1 202511 holders, $1.7bn17 holders, $11.8bn
Q2 202510 holders, $1.5bn18 holders, $10.8bn
Q3 202513 holders, $1.5bn16 holders, $13.8bn
Q4 202512 holders, $2.0bn16 holders, $14.8bn
Q1 20269 holders, $1.2bn11 holders, $12.3bn
Q2 202610 holders, $1.2bn14 holders, $15.0bn
RGEN

Repligen Corp

Holders
10
Reported value
$1.5bn
Buyers
5
Sellers
5

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
18
Reported value
$10.8bn
Buyers
8
Sellers
9

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 23 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RGEN (5)

AllianceBernstein LP, ExodusPoint Capital Management LP, Point72 Asset Management LP, Polen Capital Management LLC, Walleye Capital LLC

Only ARGX (13)

Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →